ADVANCED BREAST-CANCER
Fulvestrant for the treatment of advanced breast cancer
... positive advanced breast cancer, except for patients with life-threatening and/or rapidly progressing symptomatic disease due to extensive metastases ...of advanced breast cancer ...
23
A study of locally advanced breast cancer
... for Cancer Staging and End Results Reporting. Locally advanced breast cancer is a very common clinical scenario especially in developing countries (30-60%) possibly due to various factors like ...
115
Management of Locally Advanced Breast Cancer Fifty cases
... This is to certify that this dissertation in "MANAGEMENT OF LOCALLY ADVANCED BREAST CANCER" is a work done by Dr.B.JAYA SAI SEKHAR under my guidance during the period 2004 - 2006. This has ...
88
Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study
... 1.3%). Breast cancer was diagnosed in 1,771 of 4,450 referred women (including 287 ductal carcinomas in situ), resulting in an overall cancer detec- tion rate of ...of breast cancer ...
12
Management of Patients with Locally Advanced Breast Cancer
... Locally advanced breast cancer (LABC) continues to be a significant prob- lem in the United States and a common breast cancer presentation ...dality breast cancer treatment ...
20
Palliative care: needs of advanced breast cancer patients
... Abstract: Advanced breast cancer is characterized by many physical manifestations with the potential to undermine the quality of life (most related to the cancer and some to treatments), as ...
13
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
... Although the results of the analysis of overall survival did not meet the prespecified threshold for statistical significance, the addition of palbo- ciclib to fulvestrant resulted in an absolute pro- longation of ...
11
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer
... Abstract: Advanced breast cancer represents a therapeutic challenge for oncologists. Chemotherapy with anthracyclines and taxanes has improved survival in this setting, but resistant and refractory ...
11
Trans Sphenoidal Hypophysectomy in the Treatment of Advanced Breast Cancer
... Trans Sphenoidal Hypophysectomy in the Treatment of Advanced Breast Cancer Med J Malaysia Vol 43 No 1 March 1988 Trans Sphenoidal Hypophysectomy in the Treatment of Advanced Breast Cancer *JOHN TAN MB[.] ...
5
Clinicopathological Study of Locally Advanced Breast Cancer
... of breast cancer which are Estrogen receptor +ve neoadjuvant endocrine therapy can be considered as a part of ...the breast carcinoma ...locally advanced breast cancer was not ...
116
Optimising endocrine therapy in postmenopausal women with advanced breast cancer
... 2012 Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast[r] ...
26
Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis
... of breast cancer, advanced or metastatic, randomized controlled trial, and all known spellings of tamoxifen, anastrozole, letrozole, exemestane, fulvestrant, palbociclib, and riboci- ...
10
Present and future evolution of advanced breast cancer therapy
... most advanced oral selective dual-EGFR/HER2 reversible inhibitor in terms of clinical develop ment in breast ...of cancer cells by simultaneously targeting receptors in both cell lines, resulting in ...
18
Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa
... locally advanced breast ...long-term breast cancer ...in breast cancer patients who visited public hospitals in Johannesburg, South ...the breast at Chris Hani Baragwanath ...
8
Original Article MicroRNA-130a reduces drug resistance in breast cancer
... treat advanced breast cancer pa- tients ...paired breast cancer tissu- es from patients before and after getting Epirubicin-based neoadjuvant chemotherapy to measure the miR-130a ex- ...
7
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
... ABC: Advanced breast cancer; AIs: Aromatase inhibitors; CI: Confidence interval; CONFIRM: Comparison of Faslodex in Recurrent or Metastatic Breast Cancer trial; ER: Estrogen receptor; ...
6
The p53 breast cancer tissue biomarker in Indian women
... with breast cancer in ...of breast cancer, where it has also shown activity in tumors resistant to ...with breast cancer. In addition, among patients with locally advanced ...
8
Targeted treatment of advanced and metastatic breast cancer with lapatinib
... population. Patient characteristics were well balanced between both groups. The overall response rate (35.1% vs 25.3%) was signifi cant (odds ratio [OR] 1.7, p = 0.008). The clinical benefi t rate was 40.5% versus 31.9% ...
14
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
... the HALT-BC trial of early stage breast cancer patients. At 24 months, the bone mineral density in the lumbar spine was significantly increased by 5.6% in the denosumab group compared to a loss of 1% in the ...
8
Refractory hypercalcemia of malignancy related to vitamin D toxicity: Treatment strategies
... Hypercalcemia of malignancy (HCM) is a well- recognized phenomenon and is associated most commonly with either elevated levels of PTHrP or bone metastases [5]. The classic presentation includes an elevated serum calcium ...
5